Lindsay Borthwick

Q&A: CQDM's Diane Gosselin on catalyzing Canadian innovation in biopharma

Lindsay Borthwick
February 9, 2022

Research Money spoke with Diane Gosselin, president and CEO of the biopharmaceutical research consortium CQDM, on how Canada can reinvigorate and build its biopharmaceutical sector after the pandemic.

... Please become a Member or login to read the rest of this article ...


Other stories mentioning these organizations, people and topics
Organizations: CQDM
People: Dr Diane Gosselin
Topics: business-led innovation, commercialization of research, domestic life sciences sector, drug discovery and development, and Networks of Centres of Excellence (NCE)

Other News

The Short Report – Feb. 9, 2022: Quebec getting Canada’s first universal quantum computer, Canadian cleantech companies receive more than $52 million in SDTC funding, Ocean Supercluster announces largest project to date, public servants learn about AI, and more

Canada showed strong growth in patents for pandemic prevention technology in last two decades, CIPO report finds

Mid-career skills training will be key to addressing Canada's labour challenges

U of T medical school starts entrepreneur-in-residence program to accelerate research commercialization






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 0 free articles remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.